Key Highlights
- Loss per share of USD 0.54, where a USD 0.47 loss was expected.
- Collaboration Revenue of USD 3.9 million compared with a USD 4.87 million estimate.
- Net loss of USD 29.94 million, against USD 15.53 million.
- Cash and marketable securities stood at USD 492.9 million on September 30.
Aktis Oncology (NASDAQ:AKTS) lost USD 0.54 per share in the third quarter of 2026, against an estimated USD 0.47 loss. Collaboration revenue was USD 3.9 million, against an estimate of USD 4.87 million. The net loss was USD 29.94 million, against USD 15.53 million in the third quarter of 2025.
The loss from operations was USD 34.75 million, against USD 18.20 million. The figures appear in the company's filing for the quarter ended September 30, 2026.
Research Takes the Largest Share
Research and development expenses were USD 32.13 million, against USD 16.47 million, and general and administrative expenses were USD 6.53 million, against USD 3.32 million. Total operating expenses were USD 38.65 million, against USD 19.78 million.
Other income, net, was USD 4.8 million, against USD 2.7 million. The filing credits most of the USD 2.1 million rise to higher interest income, which came from larger average balances in cash equivalents and marketable securities. Interest income was USD 4.82 million, against USD 2.68 million.
Nine Months to September 30
The net loss for the nine months ended September 30, 2026 was USD 72.41 million, against USD 48.59 million, and the loss per share was USD 1.36. Total operating expenses were USD 96.87 million, against USD 61.94 million, and the loss from operations was USD 86.35 million, against USD 57.31 million.
Research and development cost USD 77.44 million, against USD 50.96 million, and general and administrative expenses were USD 19.43 million, against USD 10.98 million. Share-based compensation was USD 9.69 million, against USD 4.03 million.
Liquidity, Lilly Collaboration and Balance Sheet
The company believes its existing cash, cash equivalents and marketable securities, totaling USD 492.9 million at September 30, 2026, will cover its operations for a minimum of twelve months after the financial statements are issued.
The filing describes a May 2024 collaboration with Eli Lilly (NYSE:LLY) to generate anticancer radiopharmaceuticals using the company's miniprotein technology platform. It also covers the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan, both adopted in January 2026 and effective on January 8, 2026, and notes that AKY-2519 is moving into clinical trials.
The Balance Sheet shows total liabilities of USD 73.61 million, an accumulated Deficit of USD 228.97 million and total stockholders' equity of USD 458.87 million. Operating Activities used USD 70.88 million over the nine months, and financing activities provided USD 339.41 million. The filing notes that the company has lost money since inception, including USD 72.4 million and USD 48.6 million for the nine months ended September 30, 2026 and 2025.
The Quarter in Brief
Aktis Oncology reported a loss of USD 0.54 per share and a net loss of USD 29.94 million. Research and Development expenses were USD 32.13 million, and cash, cash equivalents and marketable securities were USD 492.9 million.






Please wait processing your request...